MedTrace Logo

AZD0585 Phase III Long-term Study in Japan

NCT02463071 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 383

Last updated 2018-10-01

Study results available
· View outcomes & findings →

Summary

This study is a randomised, double-blind phase III long-term study to evaluate efficacy and safety of 12 weeks and 52 weeks of AZD0585 administration compared to placebo in patients with hyperlipidemia accompanied by hypertriglyceridemia .

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

AZD0585

1g soft capsule

DRUG

AZD0585 placebo

1g soft capsule

Sponsors & Collaborators

Principal Investigators

  • Kayoko Ikeda, MD · Social medial corporation Koyokai Nakajima Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-10
Primary Completion
2017-03-11
Completion
2017-03-11

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02463071 on ClinicalTrials.gov